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Abstract 
This commentary proposes that budding tumor cell projections from focally disrupted tumor 
capsules represent a most effective target for early detection and intervention of prostate 
tumor invasion. The rationale, supporting data, and clinical applications of the hypothesis are 
discussed.  
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1. The structural features of the human pros-
tate 
The normal and pre-invasive prostate tumor ep-
ithelium, which is the histological origin of over 80% 
of the human prostate malignancies, is physically se-
parated from the stroma by the basal cells and base-
ment membrane. Basal cells are joined by intercellular 
junctions and cell surface adhesion molecules, form-
ing a largely continuous sheet encircling epithelial 
cells [1-2]. The basement membrane is composed of 
type IV collagen, laminins, and other molecules, 
forming a continuous lining surrounding the basal 
cell layer [3-4] (Fig 1). Together, the basal cell layer 
and the basement membrane constitute a morpho-
logically distinct capsule, which is a permanent 
structural element largely independent of hormonal 
regulation and the host’s bio-physiological condition 
[1-4]. The epithelial cells are held in place by inter-
cellular junctions and cell surface adhesion molecules 
(Fig 2). The epithelium is normally devoid of blood 
vessels and lymphatic ducts and totally relies on the 
stroma for its basic needs. Due to these structural re-
lationships, the physical and functional status of the 
tumor capsule significantly impacts the biological 
behavior of the epithelial cells, and the disruption of 
the tumor capsule is a pre-requisite for prostate tumor 
invasion and metastasis.  
2. Focal basal cell alterations and disruptions 
in tumor capsules  
Prostate tumor invasion is believed to be a mul-
tistage process, progressing sequentially from normal 
to hyperplasia, to prostatic intraepithelial neoplasia 
(PIN), and to invasion [5-8]. Progression from PIN to 
invasion is believed to be triggered by overproduction 
of proteolytic enzymes primarily by cancer cells, 
which cause degradation of the tumor capsule [9-10]. 
These theories are consistent with experimental data 
from tissue cultures or animal models, but they are 
hard to reconcile with four critical facts: (a) previous 
studies have revealed that some healthy men between 
19 and 29 years old demonstrated a spectrum of pro-
liferative abnormalities in the prostate, including 
atypical hyperplasia, dysplasia, and incipient adeno-
carcinoma [11-13], (b) recent studies have detected a 
DNA phenotype that is identical to the DNA structure 
of invasive prostate cancer in certain healthy men, 
and in normal prostate tissues adjacent to prostate 
cancer [14-17], (c) a majority of PIN express high le-Journal of Cancer 2010, 1 
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vels of proteolytic enzymes, but only about 30% of 
untreated PIN progress to invasive lesions during 
patients’ lifetime [18-21], and (d) results from world-
wide human clinical trials with a wide variety of 
proteolytic enzyme specific inhibitors to treat or pre-
vent tumor invasion have been very disappointing 
[22,23]. Together, these suggest that alternative me-
chanism(s) may exist for prostate tumor invasion.  
A number of clinic tests, including the mea-
surement of the serum level of prostate specific anti-
gen (PSA), MRI, and gene expression profiling, are 
increasingly used in the clinic, whereas none of those 
could predict which of the PIN lesions will progress 
[24-29]. The only established approach to monitor PIN 
progression is repeat biopsy [25-29], which is costly 
and painful. Since over 90% of prostate cancer related 
mortality result from invasion- related illnesses, and 
the incidence of PIN could be up to 16.5%-25% in 
routine or ultrasound guided prostate biopsies 
[25-29], there is an urgent need to uncover the intrin-
sic mechanism of tumor invasion, and to develop 
novel approaches to identify the specific precursor of 
invasive prostate lesions.  
Promoted by the fact that the basal cell layer is 
the sole source of tumor suppressor p63 and maspin 
in prostate [31-33], and that the absence of the basal 
cell layers is one of the most distinct morphological 
signs of invasive cancers, our resent studies have at-
tempted to identify the early signs of tumor capsule 
disruptions. Our initial study examined the physical 
integrity of basal cell layers in 50 patients with 
co-existing pre-invasive and invasive prostate tumors. 
Of 2,047 ducts and acini examined, 197 were found to 
harbor focal disruptions (the absence of basal cells 
resulting in a gap greater than the combined size of at 
least 3 basal cells) in the tumor capsule. The frequency 
of focal tumor capsule disruptions varied from none 
in 22 (44%) cases to over 1/3 of the ducts or acini with 
focal disruptions in 17 (34%) cases [34-38].  
Compared to their non-disrupted counterparts, 
focally disrupted tumor capsules displayed a number 
of unique alterations, including a significantly lower 
proliferation index and p63 expression, but a signifi-
cantly higher frequency of degeneration, apoptosis 
and infiltration of leukocytes, which are generally 
located at or near focally disrupted tumor capsules 
(Fig 3d).  
 
 
Fig 1. Structural relationships among the prostate epithelium, basal cell layer, basement membrane, and stroma. Human 
prostate sections were double immunostained for cytokeratin 34BE12 (red) and collagen IV (brown). Circles identify ep-
ithelial cells. Starts identify the stroma. Thin arrows identify the basal cell layer. Thick arrows identify the basement 
membrane. A and C: 150X. B and D: a higher magnification (400X) of A and C, respectively. Journal of Cancer 2010, 1 
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Fig 2. E-cadherin expression in epithelial cells. Sections were immunostained for cell surface adhesion molecule E-cadherin. 
Note that both the pre-invasive and invasive cancer cells (circle) show strong E-cadherin expression, and the edges of 
pre-invasive tumors are smooth without budding cells. 150X. 
 
Fig 3. Focal disruptions in tumor capsules. Human prostate sections were double immunostained with different markers. 
Circles identify focal disruptions in the tumor capsules. Arrows identify degenerated (A), isolated (B), and apoptotic (C) 
basal cells. Note that most leukocytes (brown particle-like structures) are located at or near focally disrupted capsules. 
200X. 
3. Tumor cell budding from focally disrupted 
tumor capsules  
Focal disruptions in the tumor capsule appear to 
significantly impact the morphological and biological 
presentations of associated epithelial cells. Although 
most focal tumor capsule disruptions were seen in 
PIN, a subset of normal- and hyperplastic-appearing 
ducts and acini also showed focal disruptions in their 
capsules. As shown in Fig 4, epithelial cells overlying 
focally disrupted capsules of two morphologically 
normal appearing ducts are arranged as finger- or Journal of Cancer 2010, 1 
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tongue-like projections budding from focally dis-
rupted capsules. Budding cell projections often 
punctured deep into the stroma and were morpho-
logically indistinguishable from invasive cancer cells 
(Fig 4). A majority of epithelial structures with bud-
ding cell projections were adjacent to invasive lesions 
and all budding cells from the same or different cases 
shared s similar morphological and immunohisto-
chemical profile with a substantially higher prolifera-
tion index than their parent structures [34-38].  
  These budding cell projections also expressed 
high levels of malignancy-associated markers al-
pha-methylacyl-CoA racemase (AMACR) and pros-
tate specific antigen (PSA). In contrast, cells within the 
same duct or acinus but distant focally disrupted tu-
mor capsules were largely devoid of these two mole-
cules (Fig 5). 
 
 
Fig 4. Tumor cell budding from focally disrupted tumor capsules. Human prostate tumor tissue sections were double 
immunostained for CK34BE12 (red) and Ki-67 (brown). Circles identify budding tumor cell projections. Squares identify 
normal appearing prostate ducts in which the budding cell projections are originated. Arrows identify basal cells. A&C: 
100X. B&D: 300X. 
 
Fig 5. Expression of malignancy-associated molecules. Human prostate tumor sections were double immunostained for 
CK34BE12 (red) and AMACR (A-B; brown) or PSA (C-D; brown). Circles identify budding cell projections with AMACR or 
PSA expression. Squares identify morphologically similar cells without the expression of AMACR or PSA. Arrows identify 
residual basal cell layer. A & C: 100X. B & D: a higher magnification (300X) of A&C, respectively.  Journal of Cancer 2010, 1 
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Fig 6. Differential gene expression between cells overlying focally disrupted tumor capsule (A) and cells within the tumor 
core (B). Note that budding cells from focally disrupted tumor capsule have a significantly higher expression of invasion and 
stem cell related genes. 
 Journal of Cancer 2010, 1 
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Gene expression profiling with RNA extracted 
from microdissected budding cell projections and 
their adjacent counterparts within the same tumor 
showed that budding cell projections had a signifi-
cantly higher expression of stem cell- and tumor in-
vasion-related genes [36] (Fig 6).  
4. Clinical implications of tumor cell budding 
from focally disrupted tumor capsules 
Our findings of tumor cell budding from focally 
disrupted prostate tumor capsule are consistent with 
those of a number of previous studies in human eso-
phageal and colorectal cancers, which detected a sim-
ilar pattern and frequency of tumor cell budding, and 
revealed that tumors with budding cells were signif-
icantly correlated with invasion, metastasis, and 
worse prognosis [39-41]. The results of our gene ex-
pression profiling are also in line with those of a re-
cent study, which showed that microdissected cells 
from the periphery and the center of the same ductal 
carcinoma in situ had a markedly different frequency 
and pattern in the expression of 22 genes, assessed 
with Atlas human Cancer 1.2 Arrays containing 1176 
known genes [42].  
Together, our findings suggest that tumor cell 
budding from focally disrupted tumor capsules is 
likely to represent an early sign of tumor invasion. 
O u r  f i n d i n g s  a l s o  s u g g e s t  t h a t  b u d d i n g  t u m o r  c e l l  
projections are likely to result from monoclonal pro-
liferation of an activated tumor progenitor or a bio-
logically more aggressive cell clone and represent the 
direct precursors of invasive prostate lesions. If fur-
ther validated, budding tumor cell projections from 
focally disrupted tumor capsules could be considered 
as a most effective target for early detection and in-
tervention of prostate tumor invasion for three main 
reasons. First, as focal capsule disruptions with bud-
ding cells are also seen in normal- or hyperplas-
tic-appearing ducts and acini, budding cell projections 
may also represent an early sign of prostate tumor 
progression that eventually leads to invasion. Thus, 
the development of more feasible technical ap-
proaches to detect focal capsule disruptions with 
budding epithelial cells in biopsy samples may sig-
nificantly facilitate differentiation between clinically 
aggressive and indolent pre-invasive prostate lesions, 
and also leads to identification of the specific indi-
viduals at increased risk to develop invasive prostate 
cancer. Second, as these budding cell projections are 
generally surrounded by or adjacent to leukocytes 
and other stromal cells (as shown in Fig 3), the de-
gradation products from the tumor capsules and the 
secretory products from the budding cells are likely to 
enter the blood stream. Thus, the development of a 
quantitative assay to measure the levels of these mo-
lecules in the blood samples could be potentially used 
as a screen tool to identify the individuals at greater 
risk to develop invasive prostate cancer. Third, as all 
budding cell projections within the same or different 
cases are morphologically and immunohistochemi-
cally similar, they are likely to have a very similar 
molecular profile and also share the same pathway for 
invasion. Thus, the identification of the shared mole-
cules within these cells could lead to the development 
of effective therapeutic agents to specifically target all 
these cells, which could potentially block tumor inva-
sion at the very early stage. However, it is currently 
difficult, if not impossible, to fully elucidate the mo-
lecular and biochemical profiles of these very limited 
budding cells, due to the lack of sensitive technical 
approaches.  
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